UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 113.802
NA - Nord America 10.176
AS - Asia 4.432
SA - Sud America 831
Continente sconosciuto - Info sul continente non disponibili 583
AF - Africa 139
OC - Oceania 9
Totale 129.972
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 110.355
US - Stati Uniti d'America 9.910
SG - Singapore 1.788
CN - Cina 1.331
NL - Olanda 1.119
BR - Brasile 665
SE - Svezia 585
VN - Vietnam 462
UA - Ucraina 451
DE - Germania 321
FI - Finlandia 267
GB - Regno Unito 215
FR - Francia 190
CA - Canada 138
HK - Hong Kong 135
IN - India 121
BD - Bangladesh 118
IQ - Iraq 60
RU - Federazione Russa 54
AR - Argentina 51
PK - Pakistan 50
TR - Turchia 50
KR - Corea 43
ES - Italia 42
AT - Austria 41
MX - Messico 39
ZA - Sudafrica 38
ID - Indonesia 34
CO - Colombia 30
EC - Ecuador 28
IR - Iran 27
JP - Giappone 26
MA - Marocco 25
BE - Belgio 23
PL - Polonia 20
MY - Malesia 19
IL - Israele 18
JM - Giamaica 18
TH - Thailandia 18
UZ - Uzbekistan 18
EG - Egitto 17
AE - Emirati Arabi Uniti 16
JO - Giordania 16
VE - Venezuela 16
CR - Costa Rica 15
SA - Arabia Saudita 15
LT - Lituania 14
CL - Cile 12
KE - Kenya 12
RO - Romania 12
BG - Bulgaria 11
PE - Perù 11
TN - Tunisia 11
CH - Svizzera 10
GT - Guatemala 10
IE - Irlanda 10
PH - Filippine 10
SI - Slovenia 10
HN - Honduras 9
DZ - Algeria 8
GR - Grecia 8
NP - Nepal 8
PT - Portogallo 8
PY - Paraguay 8
SV - El Salvador 7
AU - Australia 6
KZ - Kazakistan 6
OM - Oman 6
PS - Palestinian Territory 6
TW - Taiwan 6
BO - Bolivia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HU - Ungheria 5
LB - Libano 5
SC - Seychelles 5
TT - Trinidad e Tobago 5
AL - Albania 4
AZ - Azerbaigian 4
CI - Costa d'Avorio 4
CZ - Repubblica Ceca 4
GP - Guadalupe 4
NI - Nicaragua 4
UY - Uruguay 4
AO - Angola 3
CG - Congo 3
CW - ???statistics.table.value.countryCode.CW??? 3
CY - Cipro 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
RS - Serbia 3
BH - Bahrain 2
BZ - Belize 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
LK - Sri Lanka 2
Totale 129.364
Salva come PNG Salva come JPEG
Città #
Cagliari 105.907
Uta 2.942
Ashburn 1.251
Amsterdam 1.087
Singapore 946
Woodbridge 680
San Jose 678
Fairfield 636
Chandler 526
Dallas 426
Houston 376
Boardman 371
Nyköping 352
Ann Arbor 293
Beijing 286
Wilmington 270
Council Bluffs 245
Seattle 220
Cambridge 210
Los Angeles 205
Jacksonville 189
Santa Clara 181
Dearborn 178
Helsinki 174
Chicago 149
Milan 144
Ho Chi Minh City 133
Rome 130
Hong Kong 118
Lauterbourg 115
Boston 114
The Dalles 113
Shanghai 104
Buffalo 103
Nanjing 89
New York 89
Hanoi 84
Hefei 82
Dong Ket 64
São Paulo 60
San Diego 58
Salt Lake City 52
Toronto 49
Naples 46
Guangzhou 45
Nuremberg 42
Phoenix 42
Redondo Beach 42
Columbus 39
Seoul 38
Brooklyn 32
Montreal 31
Orem 31
Tampa 31
Munich 30
London 29
Changsha 28
Frankfurt am Main 28
Hebei 27
Redwood City 27
Sassari 26
Atlanta 24
Denver 24
Shenyang 24
Tokyo 24
Elk Grove Village 23
Johannesburg 23
Turin 23
Bari 22
Brussels 22
Da Nang 22
Tianjin 22
Baghdad 21
Florence 21
Newark 21
Rio de Janeiro 21
San Francisco 20
Vienna 20
Nanchang 19
Salvador 19
Curitiba 18
Jiaxing 18
Bologna 17
Chennai 17
Jinan 17
Mountain View 17
North Bergen 17
Verona 17
Warsaw 17
Washington 17
Amman 15
Lappeenranta 15
Manchester 15
Tashkent 15
Las Vegas 14
Livorno 14
Queens 14
Catania 13
Genoa 13
Haiphong 13
Totale 121.821
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 4.121
Current growth patterns in children and adolescents with thalassemia major 3.024
A genetic score for the prediction of beta-thalassemia severity 2.950
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.939
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.725
Deferasirox and children: From clinical trials to the real world 2.503
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.373
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.301
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.194
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.170
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 2.105
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 2.050
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 2.043
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 2.013
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.994
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.940
Investigating the Alpha 1Ncol mutation 1.901
Hematological phenotypes in children according to the α-globin genotypes 1.801
null 1.759
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.733
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.699
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.549
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.548
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.496
Deferasirox: pharmacokinetics and clinical experience 1.467
β-Thalassemia 1.449
Alpha-Thalassemia 1.371
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.360
A complicated disease: What can be done to manage thalassemia major more effectively? 1.352
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.336
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.295
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.290
Prospettive in Pediatria 1.249
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.213
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.201
Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice. 1.193
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.188
Combined therapy with deferiprone and desferrioxamine in thalassemia major 1.097
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 1.077
Onset of cardiac iron loading in pediatric patients 1.037
Lack of heart iron overload in patients with thalassemia intermedia. 1.036
null 1.009
Urinary hepcidin in thalassemic syndromes 922
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 909
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 903
null 886
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 880
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 856
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 851
Pregnancy in Thalassemia 833
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 807
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 784
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 778
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 776
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 769
Beta-thalassemia 754
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 749
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 745
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 745
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 744
Retrospective evaluation of different iron chelators on cardiac T2* 731
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 723
Genetic basis, pathophysiology and diagnosis 714
Pathophysiology of beta thalassaemia 714
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 707
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 705
Changing patterns of thalassaemia in Italy: a WebThal perspective. 699
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 692
Pregnancy and β-thalassemia: An Italian multicenter experience 683
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 679
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 674
Beta-Thalassemia. 669
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 656
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 650
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 637
Cholelithiasis in thalassemia major 631
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 623
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 619
null 618
Phenoconversion’ in adult patients with β-thalassemia 604
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 595
null 589
Neutropenia in patients with thalassemia major. 588
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies" 585
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 585
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 580
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 573
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 567
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 563
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 558
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 553
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload 552
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 548
null 539
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 538
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 530
Densità minerale ossea e rischio di frattura nella _ talassemia major 528
Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending 515
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 511
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) 505
Totale 114.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.348
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 189.348
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.890 0 0 0 0 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202524.749 4.381 4.815 4.101 3.125 1.580 1.876 1.983 153 416 1.342 692 285
2025/20267.995 714 343 908 696 581 833 1.081 507 676 814 497 345
2026/20272.561 224 396 777 1.150 14 0 0 0 0 0 0 0
Totale 129.972